Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 10, 2017, Pages 1397-1407

  Terauchi, Yasuo ^a   Tamura, Masahiro ^b   Senda, Masayuki ^b   Gunji, Ryoji ^c   Kaku, Kohei ^d  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sanofi KK   (Japan)

^c KOWA COMPANY LTD   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

basal insulin (or insulin therapy); glycaemic control; hypoglycaemia; randomized trial; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; PLACEBO; TOFOGLIFLOZIN; URIC ACID; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CEREBELLUM INFARCTION; COLD URTICARIA; COMORBIDITY; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; POLLAKISURIA; POLYURIA; POMPHOLYX; PRURIGO; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT DURATION; TREATMENT RESPONSE; UNCONSCIOUSNESS; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85023604677     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12957     Document Type: Article

References (41)

1. Halban PA, Polonsky KS, Bowden DW, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014;37:1751-1758.
2. Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267-282.
3. Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Diabetes Care. 2008;31(suppl 2):S131-S135.
4. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2016;39(suppl 1):S52-S59.
5. Eskesen S, Kelsberg G, Hitchcock K, Lo V. Clinical inquiries. What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes? J Fam Pract. 2006;55:1001-1003.
6. Aschner P, Sethi B, Gomez-Peralta F, et al. Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. J Diabetes Complications. 2015;29:838-845.
7. Sato S, Saisho Y, Kou K, et al. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. PLoS One. 2015;10:e0121988.
8. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
9. Jung CH, Jang JE, Park JY. A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabetes Metab J. 2014;38:261-273.
10. Mudaliar S, Polidori D, Zambowicz B, et al. Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38:2344-2353.
11. Kilov G, Leow S, Thomas M. SGLT2 inhibition with dapagliflozin: a novel approach for the management of type 2 diabetes. Aust Fam Physician. 2013;42:706-710.
12. Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs. 2014;74:939-944.
13. Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749-766.
14. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:984-993.
15. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936-948.
16. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.
17. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928-935.
18. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
19. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539-545.
20. Cefalu WT, Riddle MC. SGLT2 inhibitors: the latest “new kids on the block”!. Diabetes Care. 2015;38:352-354.
21. Ishihara H, Yamaguchi S, Nakao I, et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016;18:1207-1216.
22. Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J Diabetes Invest. 2016;7:555-564.
23. Inagaki N, Harashima S, Maruyama N, et al. Efficacy and safety of canagliflozin in combination with insulin: a double blind, randomized, placebo controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.
24. Scheen A. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54:691-708.
25. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-1662.
26. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
27. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-2161.
28. International Diabetes Federation. Guideline for management of postmeal glucose. 2007. https://www.idf.org/webdata/docs/Guideline_PMG_final.pdf. Accessed December 20, 2016.
29. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-767.
30. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587-591.
31. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403-411.
32. John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: clinical perspectives. Indian J Endocrinol Metab. 2016;20:22-31.
33. Savarese G, D'Amore C, Federici M, et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol. 2016;220:595-601.
34. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
35. Takae K, Nagata M, Hata J, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community – the Hisayama Study. Circulation J. 2016;80:1857-1862.
36. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61:225-232.
37. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Inter Med. 2012;156:405-415.
38. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815-1823.
39. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218-1227.
40. Suzuki K, Mitsuma Y, Sato T, Anraku T, Hatta M. Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes. J Clin Med Res. 2016;8:805-814.
41. Seufert J. SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543-554.